Madrigal Pharmaceuticals, Inc.
MDGL
$546.66
$12.502.34%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 71.17% | 126.84% | 210.77% | 362.03% | 1,353.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 71.17% | 126.84% | 210.77% | 362.03% | 1,353.76% |
| Cost of Revenue | 341.33% | 494.88% | 609.67% | 742.10% | 1,325.31% |
| Gross Profit | 59.15% | 114.33% | 197.01% | 348.40% | 1,355.06% |
| SG&A Expenses | 47.00% | 59.95% | 69.93% | 94.37% | 86.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 61.75% | 86.58% | 123.52% | 124.81% | 46.75% |
| Operating Income | -19.29% | -16.91% | 11.03% | 2.00% | 70.96% |
| Income Before Tax | -37.03% | -28.88% | 1.42% | -6.76% | 72.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -37.03% | -28.88% | 1.42% | -6.76% | 72.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.03% | -28.88% | 1.42% | -6.76% | 72.18% |
| EBIT | -19.29% | -16.91% | 11.03% | 2.00% | 70.96% |
| EBITDA | -19.44% | -16.98% | 11.13% | 2.06% | 71.14% |
| EPS Basic | -31.90% | -24.68% | 5.30% | -3.26% | 73.19% |
| Normalized Basic EPS | -31.89% | -24.68% | 5.30% | -0.74% | 73.19% |
| EPS Diluted | -31.90% | -24.68% | 5.30% | -3.26% | 73.19% |
| Normalized Diluted EPS | -31.89% | -24.68% | 5.30% | -0.74% | 73.19% |
| Average Basic Shares Outstanding | 3.90% | 3.37% | 4.10% | 3.39% | 3.76% |
| Average Diluted Shares Outstanding | 3.90% | 3.37% | 4.10% | 3.39% | 3.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |